Edition:
India

Inotek Pharmaceuticals Corp (ITEK.OQ)

ITEK.OQ on NASDAQ Stock Exchange Global Market

2.44USD
10:01pm IST
Change (% chg)

$-0.04 (-1.61%)
Prev Close
$2.48
Open
$2.48
Day's High
$2.49
Day's Low
$2.38
Volume
11,660
Avg. Vol
233,287
52-wk High
$7.40
52-wk Low
$0.85

Select another date:

Fri, Oct 13 2017

BRIEF-Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals

* Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals

BRIEF-‍Adage Capital Partners reports 5.55 pct stake in Inotek Pharmaceuticals

* ‍Adage Capital Partners reports 5.55 percent stake in Inotek Pharmaceuticals as of September 26 - SEC filing​

BRIEF-Braden Leonard reports 5.6 pct passive stake in Inotek Pharmaceuticals as of Sept 13 - SEC Filing

* Braden M Leonard reports 5.6 percent passive stake in Inotek Pharmaceuticals Corp as of Sept 13, 2017 - SEC Filing Source text: [http://bit.ly/2xw5tXM] Further company coverage:

BRIEF-Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases

* Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases

BRIEF-Inotek Pharmaceuticals qtrly loss per share $0.24

* Inotek Pharmaceuticals Corporation reports second quarter 2017 financial results and operational highlights

Inotek to explore strategic options after eye drug fails trial

Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company's shares tumbling 45 percent in extended trading.

Inotek to consider strategic options after eye drug fails another study

July 7 Inotek Pharmaceuticals Corp said on Friday it would evaluate its lead experimental drug and consider strategic options after the eye drug failed another trial.

BRIEF-Inotek Pharmaceuticals says evaluating strategic alternatives

* Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update

Select another date: